Erudio Healtherudio.com
Drug
Inotuzumab ozogamicin trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying inotuzumab ozogamicin: A041703. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 2 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| A041703 NCT03739814 · National Cancer Institute (NCI) | CD22-positive B-lineage acute lymphoblastic leukemia | Phase 2 | 133 | 23 | Focused | Nov 9, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| INO-VATE NCT01564784 · Pfizer StandardView → | relapsed or refractory CD22-positive acute lymphoblastic leukemia | Phase 3 | Standard | View | |||
| AALL1732 NCT03959085 · Children's Oncology Group FocusedView → | high-risk B-ALL, mixed phenotype acute leukemia, B-LLy | Phase 3 | Focused | View | |||